Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to Humans

Abstract

The development of a neovascular supply (angiogenesis) is a major aspect of tumorigenesis. Recent work has indicated that vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis. In vitro and in vivo studies have demonstrated that an anti-VEGF antibody is capable of suppressing the growth of human tumor cell lines. The following study was conducted in tumor-bearing nude mice to evaluate the concentration-response relationship of murine anti-VEGF monoclonal antibody (muMAb VEGF) so that an efficacious plasma concentration of the recombinant humanized form (rhuMAb VEGF) in cancer patients could be estimated. (This study was included in our Investigational New Drug application to support the clinical dosing regimen and projected human safety factors for the toxicology program.) Additionally, the growth dynamics of the tumors were evaluated as a function of dose to explore whether a mechanismic interpretation of tumor growth inhibition by muMAb VEGF is possible. On day 1, A673 human rhabdomyosarcoma cells (2 X 106 cells/mouse) were injected subcutaneously in 188 beige nude mice (16-24 g). Treatment with muMAb VEGF (0.05-5.0 mg/kg; n = 24/group), phosphate-buffered saline (n = 10), or anti-gp120 isotype-matched control antibody (5.0 mg/kg; n =10) began 24 hr later. Each animal received intraperitoneal injections of test material twice weekly for 4 wk. Immediately prior to each dose, 2 mice from each muMAb VEGF group were selected randomly, and plasma was collected for pharmacokinetic evaluation; at the end of the study, samples were collected from all animals for pharmacokinetic evaluation. Tumor dimensions were recorded weekly, and at the end of the study, tumor weight and dimensions were recorded. Satisfactory tumor suppression in nude mice was achieved at muMAb VEGF doses of ≥2.5 mg/kg, where the average trough muMAb VEGF plasma concentration was 30 μg/ml (concentrations in individual animals >10 μg/ml). Assuming the pharmacokinetics of rhuMAb VEGF in patients will resemble the pharmacokinetics of a similar humanized anticancer monoclonal antibodies, a clinical dosing regimen was designed to maintain the rhuMAb VEGF plasma concentration in this efficacious range. This study shows an approach that can be used to estimate a human dosing regimen from preclinical pharmacokinetic/pharmacodynamic data. Because we have just initiated clinical trials with rhuMAb VEGF, we cannot judge clinical outcome in relation to these preclinical predictions; nonetheless, it is hoped that by sharing our approach and thought processes with other investigators we can assist the discovery and development of anticancer therapeutics.

Keywords

Angiogenesis tumor growth dynamics pharmacodynamics pharmacokinetics tumorigenesis

References

Baselga J. , Tripathy D. , Mendelsohn J. , Baughman S. , Benz CC , Dan-tis L. , Sklarin NT , Seidman AD , Hudis CA , Moore J. , Rosen PP , Twaddell T. , Henderson IC , and Norton L. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14: 737-744.

Bigler SA , Deering RE , and Brawer MK (1993). Comparison of microscopic vascularity in benign and malignant prostatic tissue. Hum. Pathol. 24: 220-226.

Carmeliet P. , Ferreira, V. , Breier G. , Pollefeyt S. , Kieckens L. , Gertenstein M. , Fahrig M. , Vandenhoeck A. , Harpal K. , Eberhardt C. , Declercq C. , Pawling J. , Moons L. , Collen D. , Risau W. , and Nagy A. (1996). Abnormal blood vessel developement and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.

Ferrara N. , Carver-Moore K. , Chen H. , Dowd M. , Lu L. , O'Shea KS , Powell-Braxton L. , Hillan KJ , and Moore MW (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442.

Ferrara N. , Davis-Smyth T. (1997). The biology of vascular endothelial growth factor . Endocrinol. Rev. 18: 4-25.

Folkman J. (1991). What is the evidence that tumors are angiogenesis-dependent ? J. Natl. Cancer Inst. 82: 4-6.

Folkman J. and Klagsbrun M. (1987). Angiogenic factors. Science 235: 442—445.

Folkman J. and Shing Y. (1992). Angiogenesis. J. Biol. Chem. 267: 10931—10934 .

Garner A. (1994). Vascular diseases. In Pathobiology of Ocular Disease. A Dynamic Approach, 2nd ed., A. Garner and GK Klintworth (eds). Marcel Dekker, New York, pp. 1625-1710.

10.

Gilbert SF (1988). Developmental Biology. Sinauer , Sunderland, Massachusetts.

11.

Hamilton WJ , Boyd JD , and Mossman HW (1962). Human Embryology. William & Wilkins, Baltimore, Maryland.

12.

Horak ER , Leek R. , Klenk N. , Lejeune S. , Smith K. , Stuart M. , Green-all M. , and Harris A. (1992). Quantitative angiogenesis assessed by anti-PECAM antibodies: Correlation with node metastasis and survival in breast cancer . Lancet 340: 1120-1124.

13.

Kim KJ , Li B. , Houck K. , Winer J. , and Ferrara N. (1992). The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7: 53-64.

14.

Kim KJ , Li B. , Winer J. , Armannini M. , Gillett N. , Phillips H. , and Ferrara N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-846.

15.

Klagsbrun M. and D'Amore PA (1991). Regulators of angiogenesis . Annu. Rev. Physiol. 53: 217-239.

16.

Macchiarini P. , Fontanini G. , Hardin MJ , Squartini F. , and Angeletti C. (1992). A. relation of neovascularization to metastasis of non-small cell lung carcinoma . Lancet 340: 145-146.

17.

Press WH , Flannery BP , Teukolsky SA , and Vetterling WT (1988). Numerical Recipes in C. Cambridge University Press, New York.

18.

Smith-McCune KS and Weidner N. (1994). Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 54: 804-808.

19.

Trang JM (1992). Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In Protein Pharmacokinetics and Metabolism, BF Ferraiola , MA Mohler , and CA Gloff (eds). Plenum, New York, pp. 223-270.

20.

Vartanian RK and Weidner N. (1994). Correlation of intramural endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation. Am. J. Pathol. 144: 1188-1194.

21.

Wakui S. , Furusato M. , Sasaki H. , Akiyama A. , Kinoshito I. , Asano K. , Tokuda T. , Aizawa S. , and Ushigome S. (1992). Tumor angiogenesis in prostatic carcinoma with and without bone metastasis: A morphometric study. J. Pathol. 168: 257-262.

22.

Warren RS , Yuan H. , Matli MR , Gillett NA , and Ferrara N. (1995). Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95: 1789-1797.

23.

Weidner N. , Semple P. , Welch W. , and Folkman J. (1991). Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N. Engl. J. Med. 324: 1-6.